Solid Biosciences Inc. (SLDB)
SLDBNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$7.02
+0.4300 (+6.53%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $783.51m
- P/E
- –
- EPS, last 4 quarters
- $-1.76
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.79 to $11.45
- Average volume
- 1.27m
- Previous close
- $6.59
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $18.70, +166.4% from here
Earnings
next estimate $-0.3700Next report
Dec 2025
+2.0%
Mar 2026
-30.0%
Jun 2026
+11.6%
Sep 2026
+2.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$49.40m | -$57.31m | -$57.38m | -$57.66m |
| Net income | -$49.79m | -$56.74m | -$54.80m | -$53.95m |
News
8 latest- Solid Biosciences Receives EU Orphan Drug Designation For SGT-212 In Friedreich's Ataxia RTTNews · Oct 26, 2026
- UBS Initiates Coverage of Solid Biosciences at BuyFintel · Oct 16, 2026
- RBC Capital Initiates Coverage of Solid Biosciences at OutperformFintel · Sep 16, 2026
- Are More Solid Gains On The Horizon For SLDB? RTTNews · Jul 6, 2026
- European Commission Grants Orphan Drug Designation To Solid Biosciences' SGT-003 For DMD RTTNews · Apr 28, 2026
- Guggenheim Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationFintel · Mar 20, 2026
- Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 RTTNews · Feb 9, 2026
- Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?Zacks · Jan 16, 2026
The company
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich's ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- solidbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.